{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:28:12Z","timestamp":1761658092563,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ViiV"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jmii.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T02:09:51Z","timestamp":1565057391000},"page":"865-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression"],"prefix":"10.1016","volume":"52","author":[{"given":"Tung-Che","family":"Hung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-Jhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-0527","authenticated-orcid":false,"given":"Shu-Hsing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhen-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jheng-Lun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-0370","authenticated-orcid":false,"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach","author":"World Health Organization","key":"10.1016\/j.jmii.2019.07.002_bib1"},{"year":"2018","series-title":"Adults and adolescents living with HIV guidelines for the use of antiretroviral agents in adults and adolescents living with HIV developed by the DHHS panel on antiretroviral guidelines for adults","key":"10.1016\/j.jmii.2019.07.002_bib2"},{"year":"2018","series-title":"EACS European guidelines for treatment of HIV-positive adults in Europe","key":"10.1016\/j.jmii.2019.07.002_bib3"},{"key":"10.1016\/j.jmii.2019.07.002_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.1994.tb04231.x","article-title":"Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity","volume":"37","author":"Barry","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jmii.2019.07.002_bib5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2019.07.002_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1567-7249(02)00003-X","article-title":"Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?","volume":"1","author":"Dagan","year":"2002","journal-title":"Mitochondrion"},{"key":"10.1016\/j.jmii.2019.07.002_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(05)63513-1","article-title":"Protease inhibitor-associated hyperglycaemia","volume":"350","author":"Dub\u00e9","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2019.07.002_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/QAI.0000000000000881","article-title":"Use of abacavir and risk of cardiovascular disease among HIV-infected individuals","volume":"71","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2019.07.002_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jmii.2015.08.019","article-title":"Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients","volume":"50","author":"Huang","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2019.07.002_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-008674","article-title":"Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV","volume":"2013","author":"Lucey","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jmii.2019.07.002_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2019.07.002_bib12","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)","volume":"72","author":"Di Giambenedetto","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2019.07.002_bib13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkw379","volume":"72","author":"Perez-Molina","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2019.07.002_bib14","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2019.07.002_bib15","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","author":"Joly","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2019.07.002_bib16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2019.07.002_bib17","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1089\/aid.2011.0336","article-title":"A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir\/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study","volume":"28","author":"Ofotokun","year":"2012","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jmii.2019.07.002_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/QAI.0000000000000966","article-title":"NRTI sparing therapy in virologically controlled HIV-1 infected subjects","volume":"72","author":"Maggiolo","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2019.07.002_bib19","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir\u2013emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001\/ANRS143 randomised non-inferiority trial","volume":"384","author":"Raffi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2019.07.002_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","article-title":"Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomise","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2019.07.002_bib21","series-title":"Conference on retroviruses and opportunistic infections; Boston, MA, USA","first-page":"489","article-title":"DRV\/R\/3TC FDC for HIV-1 treatment na\u00efve patients: week 48 results of the Andes study | CROI conference","author":"Figueroa","year":"2018"},{"key":"10.1016\/j.jmii.2019.07.002_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2019.07.002_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2019.07.002_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/COH.0000000000000466","article-title":"Dolutegravir\u2013rilpivirine coformulation","volume":"13","author":"Sun","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jmii.2019.07.002_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hiv.12281","article-title":"The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir\/lamivudine+atazanavir","volume":"17","author":"Wohl","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2019.07.002_bib26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/590943","article-title":"Emergence of drug resistance in HIV type 1\u2013infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials","volume":"47","author":"Gupta","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2019.07.002_bib27","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppressi","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2019.07.002_bib28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2019.07.002_bib29","doi-asserted-by":"crossref","first-page":"35779","DOI":"10.1038\/srep35779","article-title":"Prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in taiwan","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2019.07.002_bib30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2019.07.002_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4172\/jaa.1000024","article-title":"Lopinavir\/ritonavir + tenofovir dual therapy versus lopinavir\/ritonavir-based triple therapy in HIV-infected antiretroviral na\u00efve subjects: the Kalead study","volume":"2","author":"Pinola","year":"2010","journal-title":"J Antivir Antiretrovir"},{"key":"10.1016\/j.jmii.2019.07.002_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3851\/IMP1518","article-title":"The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers","volume":"15","author":"Randell","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jmii.2019.07.002_bib33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2165\/00002018-199308040-00005","article-title":"Zidovudine toxicity. Clinical features and management","volume":"8","author":"Rachlis","year":"1993","journal-title":"Drug Saf"},{"key":"10.1016\/j.jmii.2019.07.002_bib34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12288-014-0426-9","article-title":"High incidence of zidovudine induced anaemia in HIV infected patients in Southern Odisha","volume":"31","author":"Dask","year":"2015","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118219300866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118219300866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:23:26Z","timestamp":1761657806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118219300866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1684118219300866"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2019.07.002","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}